Lantern Pharma (NASDAQ:LTRN - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Monday, March 18th. Analysts expect Lantern Pharma to post earnings of ($0.48) per share for the quarter. Individual interested in registering for the company's earnings conference call can do so using this link.
Lantern Pharma Price Performance
Lantern Pharma stock traded up $1.35 during midday trading on Friday, hitting $8.70. The company's stock had a trading volume of 763,157 shares, compared to its average volume of 210,993. Lantern Pharma has a 1-year low of $2.38 and a 1-year high of $9.59. The company has a market cap of $92.74 million, a price-to-earnings ratio of -6.21 and a beta of 1.28. The company has a 50-day moving average price of $4.66 and a two-hundred day moving average price of $4.04.
Insiders Place Their Bets
In other news, major shareholder Aaron G.L. Fletcher sold 74,297 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $4.85, for a total value of $360,340.45. Following the completion of the transaction, the insider now directly owns 62,088 shares in the company, valued at approximately $301,126.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 6.92% of the company's stock.
Institutional Trading of Lantern Pharma
A number of large investors have recently bought and sold shares of LTRN. Dimensional Fund Advisors LP acquired a new stake in shares of Lantern Pharma in the 4th quarter valued at about $51,000. Renaissance Technologies LLC lifted its position in Lantern Pharma by 82.5% in the 2nd quarter. Renaissance Technologies LLC now owns 44,900 shares of the company's stock valued at $253,000 after acquiring an additional 20,300 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Lantern Pharma by 55.8% during the second quarter. Geode Capital Management LLC now owns 90,026 shares of the company's stock valued at $508,000 after acquiring an additional 32,252 shares during the last quarter. UBS Group AG grew its stake in Lantern Pharma by 81.9% in the 1st quarter. UBS Group AG now owns 27,000 shares of the company's stock valued at $130,000 after purchasing an additional 12,159 shares during the period. Finally, Commonwealth Equity Services LLC bought a new position in Lantern Pharma in the 1st quarter valued at $97,000. 10.61% of the stock is currently owned by institutional investors and hedge funds.
Lantern Pharma Company Profile
(
Get Free Report)
Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. It develops LP-100 for treatment in combination with the class of anticancer agent known as PARP inhibitors. The company also develops LP-300 as a combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; and LP-284, a novel small molecule and DNA damaging agent for the treatment of mantle cell lymphoma and double hit lymphoma.
See Also
Before you consider Lantern Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lantern Pharma wasn't on the list.
While Lantern Pharma currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
